1. Home
  2. BGLC vs ENSC Comparison

BGLC vs ENSC Comparison

Compare BGLC & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

HOLD

Current Price

$1.47

Market Cap

4.4M

Sector

Health Care

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$0.44

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGLC
ENSC
Founded
2017
2003
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4M
3.9M
IPO Year
2019
2017

Fundamental Metrics

Financial Performance
Metric
BGLC
ENSC
Price
$1.47
$0.44
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
9.0K
22.7M
Earning Date
04-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
45.78
65.24
EPS
N/A
N/A
Revenue
$7,424,911.00
$5,066,650.00
Revenue This Year
N/A
$55.01
Revenue Next Year
N/A
$1,033.97
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$0.23
52 Week High
$6.10
$2.75

Technical Indicators

Market Signals
Indicator
BGLC
ENSC
Relative Strength Index (RSI) 42.67 62.29
Support Level $1.22 $0.34
Resistance Level $1.88 $0.63
Average True Range (ATR) 0.11 0.04
MACD 0.00 -0.00
Stochastic Oscillator 35.94 76.03

Price Performance

Historical Comparison
BGLC
ENSC

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: